Subscribe to RSS

DOI: 10.1055/s-0043-1771048
Evaluation of Biological Mechanisms of Quanduzhong Capsule for Treating Osteoporosis by Integrating Untargeted Metabolomics and Network Pharmacology

Abstract
Osteoporosis (OP) is a metabolic disease characterized by bone formation and resorption disturbances. Quanduzhong Capsule (QDZC) is a common treatment for OP in China; however, the effective components and metabolites of the drug after oral administration remain largely unknown. This study aims to identify the active components, analyze the metabolite changes, and investigate the underlying mechanism against OP. In the study, ovariectomy-induced rat OP model was established, then treated with QDZC. Alendronate sodium tablets (ASTs) were used as a reference drug. The chemical constituents of QDZC were analyzed by UPLC-QTOF-MS (ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry) and network pharmacology. The metabolomics was used to analyze differences in serum metabolites of rats in different groups [Sham, Model, Model + QDZC, and Model + AST] at 4, 8, and 12 weeks. Body weight and bone mineral density (BMD) were assessed. Enzyme-linked immunosorbent assay was used to determine serum levels of Akt, p-Akt, ERK, and p-ERK. Our data suggested 86 different chemicals from QDZC, including nine core compounds. QDZC significantly regulated 25 biomarkers linked to arachidonic acid metabolism and unsaturated fatty acid biosynthesis, and promoted serum expression of Akt, p-Akt, ERK, and p-ERK. QDZC might act by activating PI3K-Akt and MAPK signaling pathways. In addition, QDZC may use arachidonic acid derivatives to inhibit osteoclast generation and bone resorption and enhance calcitriol formation to improve calcium absorption and increase bone mass.
Publication History
Received: 08 February 2023
Accepted: 14 June 2023
Article published online:
03 August 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377 (9773): 1276-1287
- 2 Tang SS, Yin XJ, Yu W. et al. Prevalence of osteoporosis and related factors in postmenopausal women aged 40 and above in China [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 2022; 43 (04) 509-516
- 3 Wang YP. Epidemiological Investigation and TCM Syndrome Characteristics of Early Osteoporosis [in Chinese]. Changchun: Changchun University of Chinese Medicine; 2022
- 4 Zhao JJ, Cao YJ, Sun JX. et al. Prevalence and influencing factors of osteoporosis among adults in Hebei province. [in Chinese]. Chin J Publ Health 2022; 38 (06) 749-751
- 5 Zhang C, Tan L, Zhu W, Yang Z, Guo M. Research progress on prevention and treatment of osteoporosis by Eucommia ulmoides. International Journal of Clinical and Experimental Medicine Research. 2022; 6 (03) 286-294
- 6 Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China. 2010 ed. Beijing: Chinese Medicine Science and Technology Press; 2010: 168-169
- 7 He M, Jia J, Li J. et al. Application of characteristic ion filtering with ultra-high performance liquid chromatography quadrupole time of flight tandem mass spectrometry for rapid detection and identification of chemical profiling in Eucommia ulmoides Oliv. J Chromatogr A 2018; 1554: 81-91
- 8 Huang Q, Tan JB, Zeng XC, Wang YQ, Zou ZX, Ouyang DS. Lignans and phenolic constituents from Eucommia ulmoides Oliver. Nat Prod Res 2021; 35 (20) 3376-3383
- 9 Huang L, Lyu Q, Zheng W, Yang Q, Cao G. Traditional application and modern pharmacological research of Eucommia ulmoides Oliv. Chin Med 2021; 16 (01) 73
- 10 Wang CY, Tang L, He JW, Li J, Wang YZ. Ethnobotany, phytochemistry and pharmacological properties of Eucommia ulmoides: a review. Am J Chin Med 2019; 47 (02) 259-300
- 11 Liu P, Wang L, Du Q, Du H. Chemotype classification and biomarker screening of male Eucommia ulmoides Oliv. flower core collections using UPLC-QTOF/MS-based non-targeted metabolomics. PeerJ 2020; 8: e9786
- 12 He X, Wang J, Li M. et al. Eucommia ulmoides Oliv.: ethnopharmacology, phytochemistry and pharmacology of an important traditional Chinese medicine. J Ethnopharmacol 2014; 151 (01) 78-92
- 13 Zhang ZL, Zuo YM, Li YY, Chen LY, Liu RH. Phenylpropanoids constituents of Eucommia ulmoides leaves. [in Chinese]. Zhong Yao Cai 2014; 37 (03) 421-423
- 14 Li J, Wang M, Wang X, Sun L, Zhao C, Zhao M. Rapid characterization of the chemical constituents of Duzhong Jiangya tablet by HPLC coupled with Fourier transform ion cyclotron resonance mass spectrometry. J Sep Sci 2020; 43 (24) 4434-4460
- 15 Ding Y, Dou D, Guo Y, Li Q. Simultaneous quantification of eleven bioactive components of male flowers of Eucommia ulmoides oliver by HPLC and their quality evaluation by chemical fingerprint analysis with hierarchical clustering analysis. Pharmacogn Mag 2014; 10 (40) 435-440
- 16 Bai MM, Shi W, Tian JM. et al. Soluble epoxide hydrolase inhibitory and anti-inflammatory components from the leaves of Eucommia ulmoides Oliver (duzhong). J Agric Food Chem 2015; 63 (08) 2198-2205
- 17 Takamura C, Hirata T, Yamaguchi Y. et al. Studies on the chemical constituents of green leaves of Eucommia ulmoides Oliv. J Nat Med 2007; 61 (02) 220-221
- 18 Deyama T, Ikawa T, Kitagawa S, Nishibe S. The constituents of Eucommia ulmoides OLIV. V. Isolation of dihydroxydehydrodiconiferyl alcohol isomers and phenolic compounds. Chem Pharm Bull (Tokyo) 1987; 35 (05) 1785-1789
- 19 Hiraiwa M, Ozaki K, Yamada T. et al. mTORC1 activation in osteoclasts prevents bone loss in a mouse model of osteoporosis. Front Pharmacol 2019; 10: 684
- 20 Hu S, Wang S. The role of SIRT3 in the osteoporosis. Front Endocrinol (Lausanne) 2022; 13: 893678
- 21 Hu SJ, Cheng G, Zhou H. et al. Identification of novel cannabinoid CB2 receptor agonists from botanical compounds and preliminary evaluation of their anti-osteoporotic effects. Molecules 2022; 27 (03) 702
- 22 Huang M, Wang Y, Wang Z. et al. miR-134-5p inhibits osteoclastogenesis through a novel miR-134-5p/Itgb1/MAPK pathway. J Biol Chem 2022; 298 (07) 102116
- 23 Sánchez-de-Diego C, Pedrazza L, Pimenta-Lopes C. et al. NRF2 function in osteocytes is required for bone homeostasis and drives osteocytic gene expression. Redox Biol 2021; 40: 101845
- 24 Stiffel V, Amoui M, Sheng MHC, Mohan S, Lau KHW. EphA4 receptor is a novel negative regulator of osteoclast activity. J Bone Miner Res 2014; 29 (04) 804-819
- 25 Tanaka T, Takahashi A, Kobayashi Y. et al. Foxf2 represses bone formation via Wnt2b/β-catenin signaling. Exp Mol Med 2022; 54 (06) 753-764
- 26 Wang Y, Jia Y, Xu Y. et al. Exploring the association between glutathione metabolism and ferroptosis in osteoblasts with disuse osteoporosis and the key genes connecting them. Comput Math Methods Med 2022; 2022: 4914727
- 27 Xuan Y, Wang J, Zhang X. et al. Resveratrol attenuates high glucose-induced osteoblast dysfunction via AKT/GSK3β/FYN-mediated NRF2 activation. Front Pharmacol 2022; 13: 862618
- 28 Zhang Y, Kou Y, Yang P. et al. ED-71 inhibited osteoclastogenesis by enhancing EphrinB2-EphB4 signaling between osteoclasts and osteoblasts in osteoporosis. Cell Signal 2022; 96: 110376
- 29 Zhang Y, Yang M, Zhang S. et al. BHLHE40 promotes osteoclastogenesis and abnormal bone resorption via c-Fos/NFATc1. Cell Biosci 2022; 12 (01) 70
- 30 Wang S, Wang S, Wang X. et al. Effects of icariin on modulating gut microbiota and regulating metabolite alterations to prevent bone loss in ovariectomized rat model. Front Endocrinol (Lausanne) 2022; 13: 874849
- 31 Guan H, Zhao L, Cao H, Chen A, Xiao J. Epoxyeicosanoids suppress osteoclastogenesis and prevent ovariectomy-induced bone loss. FASEB J 2015; 29 (03) 1092-1101
- 32 Yang S, Lin L, Chen JX. et al. Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-α via MAPK and PI3K/Akt signaling pathways. Am J Physiol Heart Circ Physiol 2007; 293 (01) H142-H151
- 33 Abshirini M, Ilesanmi-Oyelere BL, Kruger MC. Potential modulatory mechanisms of action by long-chain polyunsaturated fatty acids on bone cell and chondrocyte metabolism. Prog Lipid Res 2021; 83: 101113
- 34 Lips P, van Schoor NM. The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab 2011; 25 (04) 585-591
- 35 Martini G, Mignarri A, Ruvio M. et al. Long-term bone density evaluation in cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment. Calcif Tissue Int 2013; 92 (03) 282-286
- 36 Epsley S, Tadros S, Farid A, Kargilis D, Mehta S, Rajapakse CS. The effect of inflammation on bone. Front Physiol 2021; 11: 511799
- 37 Lamon-Fava S, So J, Mischoulon D. et al. Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation. Prostag Leukotr Ess 2021; 164: 102219
- 38 Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994; 9 (10) 1643-1649
- 39 Chen LP, Deng MT, Chuan DU, Fang N, Luo J, Liu RH. A study of quercetin extracted from eucommia leaf promoting the proliferation of bone marrow derived mesenchymal stem cells through the phosphorylation of ERK [in Chinese]. Lishizhen Medicine and Materia Medica Research 2014; 25 (12) 2845-2847
- 40 Becherini L, Gennari L, Masi L. et al. Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor α gene and their relationship to bone mass variation in postmenopausal Italian women. Hum Mol Genet 2000; 9 (13) 2043-2050